These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32375866)

  • 21. Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.
    Yu EY; Cheung IY; Feng Y; Rabie MO; Roboz GJ; Guzman ML; Cheung NV; Lue NF
    Neoplasia; 2019 Jul; 21(7):689-701. PubMed ID: 31128432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells.
    Yu EY; Cheung NV; Lue NF
    J Hematol Oncol; 2022 Aug; 15(1):117. PubMed ID: 36030273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G-quadruplex stabilizer Tetra-Pt(bpy) disrupts telomere maintenance and impairs FAK-mediated migration of telomerase-positive cells.
    Shen Z; Zheng R; Yang H; Xing S; Jin X; Yan H; Zhu J; Mei Y; Lin F; Zheng X
    Int J Biol Macromol; 2022 Jul; 213():858-870. PubMed ID: 35697164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.
    Hartlieb SA; Sieverling L; Nadler-Holly M; Ziehm M; Toprak UH; Herrmann C; Ishaque N; Okonechnikov K; Gartlgruber M; Park YG; Wecht EM; Savelyeva L; Henrich KO; Rosswog C; Fischer M; Hero B; Jones DTW; Pfaff E; Witt O; Pfister SM; Volckmann R; Koster J; Kiesel K; Rippe K; Taschner-Mandl S; Ambros P; Brors B; Selbach M; Feuerbach L; Westermann F
    Nat Commun; 2021 Feb; 12(1):1269. PubMed ID: 33627664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
    Grobelny JV; Kulp-McEliece M; Broccoli D
    Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promotor region rearrangements analyzed in high-risk neuroblastomas by FISH method and whole genome sequencing.
    Kawashima M; Ueda Y; Kurihara S; Hiyama E
    Int J Clin Oncol; 2020 Dec; 25(12):2166-2174. PubMed ID: 32894394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral diversity of telomere length in individual neuroblastoma tumors.
    Pezzolo A; Pistorio A; Gambini C; Haupt R; Ferraro M; Erminio G; De Bernardi B; Garaventa A; Pistoia V
    Oncotarget; 2015 Apr; 6(10):7493-503. PubMed ID: 25595889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).
    Jeitany M; Pineda JR; Liu Q; Porreca RM; Hoffschir F; Desmaze C; Silvestre DC; Mailliet P; Junier MP; Londoño-Vallejo A; Ségal-Bendirdjian E; Chneiweiss H; Boussin FD
    Int J Cancer; 2015 Apr; 136(7):1546-58. PubMed ID: 25175359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
    Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
    Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma.
    Vaid R; Thombare K; Mendez A; Burgos-Panadero R; Djos A; Jachimowicz D; Lundberg KI; Bartenhagen C; Kumar N; Tümmler C; Sihlbom C; Fransson S; Johnsen JI; Kogner P; Martinsson T; Fischer M; Mondal T
    Nucleic Acids Res; 2024 Mar; 52(5):2648-2671. PubMed ID: 38180812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
    Waitkus MS; Erman EN; Reitman ZJ; Ashley DM
    Neuro Oncol; 2024 Jun; 26(6):1012-1024. PubMed ID: 38285162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells.
    Binz N; Shalaby T; Rivera P; Shin-ya K; Grotzer MA
    Eur J Cancer; 2005 Dec; 41(18):2873-81. PubMed ID: 16253503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. G-quadruplex Stabilization Fuels the ALT Pathway in ALT-positive Osteosarcoma Cells.
    Amato R; Valenzuela M; Berardinelli F; Salvati E; Maresca C; Leone S; Antoccia A; Sgura A
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32183119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
    Fasching CL; Bower K; Reddel RR
    Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
    Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomere maintenance as therapeutic target in embryonal tumours.
    Shalaby T; Hiyama E; Grotzer MA
    Anticancer Agents Med Chem; 2010 Mar; 10(3):196-212. PubMed ID: 20017721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immortalized cells with no detectable telomerase activity. A review.
    Reddel RR; Bryan TM; Murnane JP
    Biochemistry (Mosc); 1997 Nov; 62(11):1254-62. PubMed ID: 9467849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
    De Vitis M; Berardinelli F; Sgura A
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
    Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.